Patients with 2 CFH risk alleles and no ARMS2 risk alleles progressed more with zinc-containing treatment compared with placebo , with a hazard ratio ( HR ) of 3.07 ( P = 0.0196 ) for zinc and 2.73 ( P = 0.0418 ) for AREDS formulation ( AF ) .